Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

mong existing oral OAB treatments, according to Dr. Sand. "Watson's oxybutynin gel is an elegant topical formulation that is clear, odorless and fast drying and will offer healthcare providers a unique treatment option for OAB patients," said Dr. Sand.

The Phase 3 multi-center, double blind, placebo-controlled study evaluated the efficacy and safety of OTG in 789 patients with overactive bladder. The primary objective of the study was to demonstrate that daily treatment of a 1g dose (approximately 1 mL) of OTG for 12 weeks was superior to placebo for the relief of OAB symptoms. Changes from baseline to endpoint were calculated from a three-day patient urinary diary and included a reduction in incontinence episodes and urinary frequency, and an increase in void volume. Additionally, 216 patients participated in a 14-week, open label, safety-extension study for a total of 26 weeks. During the double-blind portion of the trial, highly statistically significant improvements relative to placebo were seen on all of these endpoints.

Secondary endpoints also included a patient assessment of incontinence-specific, quality-of-life measures using multiple validated instruments including the Incontinence Impact Questionnaire (IIQ) and the King's Health Questionnaire, which indicated a significant positive effect of OTG treatment on quality-of-life total and subscale scores at endpoint in comparison with placebo.

OTG was well tolerated in the study. No serious adverse events related to the treatment were reported. Dry mouth (6.9%) and application site pruritis (2.1%) were the only treatment-related side effects reported at levels greater than 2%. Treatment-related adverse events that resulted in study discontinuation during the double-blind period were low (1.8%) and the similar for both the treatment and placebo groups.

Phase 1 studies have demonstrated that the steady-state plasma levels of oxybutynin show little fluctuation during the 24-hour dosin
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 CEFALY Technology , ... stimulation device specifically authorized for use prior to the ... a new PET trial showing that the Cefaly device ... brain in migraine patients, namely the orbitofrontal cortex and ... scan, which is an imaging test of the brain, used a radioactive ...
(Date:6/1/2015)... SETAUKET, N.Y. , June 1, 2015 /PRNewswire/ ... (NASDAQ: HRTX ) today announced positive, top-line ... study.  MAGIC evaluated the efficacy and safety of ... candidate SUSTOL ® (granisetron injection, extended release) ... intravenous (IV) neurokinin-1 (NK 1 ) receptor antagonist ...
(Date:6/1/2015)... 2015   OTC Markets Group Inc. ... financial marketplaces for 10,000 U.S. and global securities, ... Diego -based biopharmaceutical company, on its NASDAQ ... public venture market for entrepreneurial and development stage ... "We,re happy to congratulate OncoSec ...
Breaking Medicine Technology:New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2New cancer therapy study results - MAGIC Trial 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... and drug withdrawal, CHICAGO, May 15, 2007 /PRNewswire/ ... and physicians commissioned by the National,Headache Foundation and ... migraine patients are currently taking potentially,addictive medications that ... by the U.S. Food and Drug Administration for ...
... , LONDON, UK and ATLANTA, US, May 14, ... Inc. (NASDAQ:SCRX) today,announce the successful completion of the ... a calcium ,channel blocking agent for the treatment ... the new Sular formulation is,bioequivalent to Sciele's currently ...
Cached Medicine Technology:Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3
(Date:6/2/2015)... 02, 2015 The Radiosurgery Society® ... from the RSSearch® Patient Registry evaluating the treatment ... (SBRT) for the treatment of centrally located primary ... , The study, published in the May, ... included 111 patients with 114 centrally located lung ...
(Date:6/2/2015)... Colorado (PRWEB) June 02, 2015 ... Chief Medical Officer at the Steadman Philippon Research Institute, ... Too Early for Single Sport Specialization? ” This was ... Sports Medicine (AOSSM) Research Committee that was recently published ... data for this project was limited, there is evidence ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Each year, ... Insiders’ Choice Beauty Awards. This year, the organization’s members ... the winner of the QVC® Beauty Quest Award at ... results-driven Micro Emulsion (ME) Technology and 2-in-1 approach to ... Also noting the brand’s loyal consumer and professional fan ...
(Date:6/2/2015)... View, CA (PRWEB) June 02, 2015 ... mandated vaccination schedule for children to attend public or ... Judiciary and Education but bypassed the Appropriations Committee (Sacramento ... floor 25-10 despite contentious hearings. , “We believe ... Personal Belief Exemptions (PBEs) more than it will (the) ...
(Date:6/1/2015)... June 02, 2015 The National ... Wirski as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this prestigious honor,” said NAPW President Star Jones. “Job ...
Breaking Medicine News(10 mins):Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2
... Data that shed new light on,the treatment of ... immune thrombocytopenic purpura, and venous,thrombosis in relation to ... 49th Annual Meeting of the American Society of,Hematology ... this new research,on Saturday, December 8, from 10:00 ...
... is a clear link between GABA a chemical ... in the brain and nicotine dependence, according ... of Neuropsychopharmacology (ACNP) annual meeting. Researchers discovered that nicotine ... could potentially help curb the pleasurable effects of nicotine ...
... link between mitochondria, memory and socialization , FRIDAY, ... respiration deficiencies in mitochondria (the source of energy ... behavior and spatial memory, Japanese researchers report. , ... link between mitochondrial malfunction and mental illness in ...
... more invasive treatment is necessary, researchers say , , FRIDAY, Dec. 7 ... test to detect lung cancer, according to a Duke University Medical ... Dec. 10 issue of the Journal of Clinical Oncology , ... RBP, SCC and AAT -- may provide a simple follow-up for ...
... that we must remain vigilant,in protecting women,s access to ... care professionals who provide that care, WASHINGTON, Dec. ... President and CEO of the National Abortion,Federation, on the ... Albuquerque,NM:, As the professional association of abortion providers, ...
... KING OF PRUSSIA, Pa., Dec. 7 Universal ... that its Board of Directors,authorized an additional 5 ... shares remaining under previously announced authorizations.,Pursuant to the ... time as,conditions allow, may purchase shares on the ...
Cached Medicine News:Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 2Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 3Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 4Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 5Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 6Health News:Study suggests nicotine addiction might be controlled by influencing brain mechanisms 2Health News:Blood Test to Detect Lung Cancer Being Eyed 2
... Savant offers several different two-stage, oil-sealed, rotary ... freeze drying applications. Each pump comes complete ... Kit) and and Oil Mist Filter (EMF-10). ... full gas ballast to keep the oil ...
Produces vacuum pressures required for 96 well kits...
Inquire...
... The Perfect Single Vac ... one 96-well plate in 30 ... with an "open/closed" switch and ... for easy operation. contains vacuum ...
Medicine Products: